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S274 Poster Session IIprophylaxis. Here we report the combined, updated results from
a consecutive case-series of 58 patients with MDS who under-
went RI-HCT from 2000 to 2008 and received either CSA/
MMF (n5 29) or FK/SIR (n5 29)-based GVHD prophylaxis.
All patients received Flu 125 mg/m2 and Mel 140 mg/m2 fol-
lowed by allogeneic HCT (PBSC: n5 52, BM: n5 6) from an
HLA-identical sibling (SIB: n5 21) or unrelated donor (MUD:
n5 37). For MUD transplants a short course of methotrexate
was added to CSA/MMF or FK/SIR. The median age was
53.5 years (range: 20-71). Diagnoses at transplant were RA
(n5 21), RARS (n5 1), and RAEB/RAEBT (n5 36). Cytoge-
netic risk was low in 15, intermediate in 20, high in 23 patients.
By IPSS criteria, two had low, 24 had int-1, 20 had int-2, and 12
had high-risk MDS. Fifteen patients had therapy-related MDS
and 13 had a prior autologous HCT. The baseline patient and
transplant characteristics were similar between CSA/MMF and
FK/SIR except for more mismatch transplants in FK/SIR (34%
vs. 10%, p5 0.02). The median follow-up for surviving patients
was 38 months (range: 24-68) for the CSA/MMF group and
16 months (range: 4-39) for the FK/SIR group. All but two pa-
tients engrafted with the median neutrophil recovery at 15 days
(range: 11-39). The 2-year disease-free survival (DFS), relapse,
and non-relapse mortality (NRM) for the entire cohort were
63% (54-70%), 12% (6-24%), and 26% (19-36%), respectively.
By univariate analysis, there was a trend for improved DFS in
FK/SIR (79% at 1 year) compared with CSA/MMF (55%,
p5 0.1). When adjusted for mismatch transplants in multivariate
analysis, the use of FK/SIR was significantly associated with im-
proved DFS (HR5 3.99 [CI: 1.4-11.5], p5 0.01), attributable to
reduced NRM with FK/SIR (HR5 6.14 [CI: 1.5-26.1],
P5 0.01). While we observed no significant difference in grade
II-IV acute GVHD between the two groups, there was a signifi-
cant reduction in grade IV GVHD in FK/SIR (0% versus 26%,
p\0.01). In conclusion, RI-HCT is associated with a promising
long-term result in MDS with improved outcomes using FK/
SIR-based GVHD prophylaxis.312
TOXOPLASMA GONDII INFECTION IN 34 PTS SUBMITTED TO HEMATO-
POIETIC STEM CELL TRANSPLANTATION: ANALYSIS FROM A SINGLE IN-
STITUTION
Vasconcelos, R., Fortier, S.C., Cunha, C.A., Piazzera, F.Z., Morando, J.,
Bitencourt, M.A., Pasquini, R., Zanis Neto, J., Funke, V.,
Bonfim, C.M.S. Federal University of Parana, Curitiba, PR, Brazil
Introduction:Toxoplasmosis is a rare and aggressive infection after
allogeneic HSCT. In Brazil we observe a high incidence of positive
serology before HSCT and therefore many pts are at risk of reacti-
vation.
Objective: Analyze the outcome of 34 pts who developed toxoplas-
mosis infection after SCT in a single institution.
Material and methods: Retrospective analysis of 34 pts submitted
to an allogeneic HSCT who developed toxoplasmosis between 04/
1984 – 11/2007. Age: 1-45ys(M: 20ys). Gender: 17 M/17F. 91%
had a positive serology (IgG) before transplant. Diagnosis: Bone
Marrow failures: 13pts; Malignant diseases: 21pts). Preparatory reg-
imen:BU +CY:18pts;TBI based regimens:9pts; Fludarabine based
regimens:3pts; CY only: 4pts. 25pts (73%) received a HSCT from
related donors while 9pts were transplanted from unrelated ones.
Toxoplasmosis was classified as definitive, probable, possible or iso-
lated infection according to the diagnostic criteria proposed by
EBMTR.In our BMT Unit, PCR tests were performed in blood
and/or cerebrospinal fluid from March 2000 in all suspected cases.
Toxoplasmosis was identified by PCR, biopsies or necropsy. Statis-
tical analysis was performed using SPSS. Overall survival was esti-
mated using the Kaplan-Meier method. Multivariate analysis was
performed by Cox method.
Results: In this group, only 9pts are alive between 1260- 6385 days
after HSCT(M: 3956d) with an OS of 31,8%(5ys). Toxoplasmosis
was diagnosed at a median of 85days after HSCT (range:26- 3035
days).Toxoplasmosis was defined as definitive in 22 pts(12 pts –
necropsy), probable:1pt; possible:6pts and infection:5pts. Site of in-
fection: Disseminated: 2pts; Central Nervous System (CNS):14pts;lung 8pts; liver: 1pt; ocular: 2pts; skin: 1pt and heart:1pt. Toxoplas-
mosis infection(only):5pts. Primary graft failure occurred in 5/
34pts and all died (4 deaths were related to toxoplasmosis). Acute
GVHD grade II-IV was observed in 22pts while 11 had Chronic
GVHD(extensive: 9pts). 25pts died between 38-4378days after
SCT (M: 90days) and toxoplasmosis was considered the major
cause of death in 13 pts. Survival was lower in the unrelated group
when compared to the related one even though it did not reach sta-
tistical significance in the univariate analysis (68days  254 days
p5 0.097). All pts with the diagnosis of Bone Marrow failures
died (7 related to toxoplasmosis).
Conclusions: 1) We observed a high mortality rate (52%) in this
group of patients and a high prevalence of CNS infection.313
HORIZONTAL GENE TRANSFER THROUGH APOPTOTIC BODIES CONFERS
A NOVEL MECHANISM OF EPITHELIAL CHIMERISM AFTER ALLOGENEIC
HCT
Waterhouse, M.1, Themeli, M.2, Finke, J.1, Spyridonidis, A.2 1Freiburg
University Medical Center, Freiburg, Baden Wuettemberg, Germany;
2Patras University Hospital, Patras, Greece
Animal and human studies have shown that after allogeneic he-
matopoietic cell transplantation (HCT) low percentage of epithe-
lial cells containing donor-derived genome emerge. The
mechanisms underlying this phenomenon are unknown. We inves-
tigated using an in vitro model if horizontal gene transfer could ac-
count as a possible mechanism for epithelial chimerism after
allogeneic HCT. Briefly, keratinocyte HaCaT cells (Y-chromo-
some neg) were cocultivated with non-apoptotic Jurkat cells (Y
chromosome pos) or Jurkat cells in which apoptosis was induced
with Camptothecin. Jurkat cells were labeled with CMFDA or
BrdU in order to track the fate of apoptotic bodies and genomic
material respectively. HaCaT cells co-cultivated with non-apopto-
tic Jurkat cells for 24-72 h did not show any CMFDA, BrdU or
FISH-Y chromosome signal. In contrast, co-cultivation of HaCaT
cells with Jurkat apoptotic bodies resulted in CMFDA signal in
28% of the HaCaT cells, BrdU signal in 18% and Y-chromosome
signal in 3% of the cells. Importantly, BrdU and Y-chromosome
signals were observed in the cytoplasm and within the nucleus of
the HaCaT cells as evaluated by confocal microscopy. Metaphases
from the BrdU+ HaCaT cells confirmed that the BrdU signal was
located within the isolated chromosomes suggesting the creation of
hybrid chromosomes. Incorporation of the transferred genomic
material in the HaCaT host genome was inhibited by cytochalasin
(inhibitor of phagocytosis), increased 3-fold by bafylomicin (inhibi-
tion of lysosomal degradation) and 2-fold when HaCat cells were
repeatedly exposed to Jurkat apoptotic bodies. In order to evaluate
expression of the transferred genomic material, we co-cultivated
HacaT cells with intact or apoptotic GFP-transfected JvM cells.
Cocultivation with non-apoptotic GFP+ cells resulted in no GFP
expression in Hacat cells. In contrast, cocultivation of Hacat cells
with GFP+ apoptotic bodies resulted in a 6-fold increase in the
mean GFP fluorescence in HaCaT cells. Taken together, our in
vitro model suggests horizontal gene transfer through apoptotic
bodies as a possible mechanism explaining epithelial chimerism
after allogeneic HCT.314
CRYPTIC GENOMIC ALTERATIONS IN AML PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION BY SNP DNA PROFILING
Waterhouse, M., Pfeifer, D., Pantic, M., Alf, Z., Bertz, H., Finke, J.
Freiburg University Medical Center, Freiburg, Baden-Wuettemberg,
Germany
Allogeneic hematopoietic cell transplantation (HCT) is the most
effective curative therapy in many patients with hematologic malig-
nancies such as acute myeloid leukemia (AML). Cytogenetics stud-
ies stratify patients into three groups of prognosis according to the
overall survival. These classifications are not fully predictive of
Poster Session II S275response. Genomic technologies can identify molecular subgroups
with distinct genomic signatures. We investigated the genomic
changes in patients with AML undergoing HCT using DNA mi-
croarrays. We analyzed 11 patients before HCT and at relapse after
HCT, 6 patients had a normal karyotype at diagnosis and 5 had ab-
normal karyotype with different types of aberrations. After high
resolution of whole genome DNA profiling analysis 5 of the 6 pa-
tients with normal karyotype showed genomic aberrations (GA) in
the form of gains and losses (5/5 gains/losses) in several regions of
different chromosomes with a median of 2 GA per case. The ab-
normal karyotype group, in addition to the cytogenetically detected
aberrations GA were present in 2 out of 5 patients (5/4 gains/los-
ses). Overall 64% of the patients had GA, not detected by conven-
tional cytogenetics. All FAB subtypes of AML showed GA, being
M5 and secondary AML both with more numerous GA (average:
12 and 17 GA respectively). At relapse 6 patients increased the
number of GA, (median of 7 GA per case), while 3 patients pre-
sented a reduced number of GA (median 2 GA per case). The re-
maining 2 patients showed no additional changes. Before
transplantation 16 chromosomes showed GA with a median of 3
GA per chromosome, average size of gains and losses were 1568
and 8046 kb respectively. At relapse 19 chromosomes had GA
with a median of 4 GA per chromosome, average size of gains
and losses were 697 and 8011 kb respectively. Chromosomes 11,
14 and 21 showed no GA at any time point. Our preliminary
data demonstrate that AML is a genomically heterogeneous disease
with a high incidence of small non recurrent DNA GA that can be
detected even in cases with normal karyotype. Cryptic genomic
changes are likely to play a role in relapse after allogeneic trans-
plantation.315
CLADRIBINE (2CDA) IS COMPARABLE TO FLUDARABINE IN A BUSULFAN-
BASED REDUCED- INTENSITY REGIMEN
Yakushijin, K., Fukuda, T., Asakura, Y., Kurosawa, S., Hiramoto, N.,
Tada, K., Nishinohara, M., Maeda, T., Hagiwara, A., Ueno, N.,
Kamiyama, Y., Mori, M., Kim, S.-W., Mori, S., Tanosaki, R.,
Heike, Y., Takaue, Y. National Cancer Center Hospital, Tokyo, Japan
Reduced-intensity stem cell transplantation (RIST) with a purine
analog most often involves fludarabine (Flu). The alternative drug,
2CdA, is rarely used partly because of a potential risk of renal
toxicity. We retrospectively reviewed the medical records of 282
patients (median age, 54 y; range, 21-68) with various hematolog-
ical malignancies who underwent RIST between 1999 and 2007
with a conditioning regimen that consisted of busulfan (po 8 mg/
kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg, n5 71, C-group) or Flu (180 mg/m2, n5 211, F-group). Se-
venty-four patients also received 2-4 Gy of TBI. The donor was re-
lated (BM 8, PB 177) in 185 patients, and unrelated in 97 (BM 79,
PB 1, CB 17). GVHD prophylaxis consisted of cyclosporine (CSP,
starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml, n5 232) or tacrolimus (starting dose 0.03 mg/kg/day civ,
target whole blood conc. 10-20 ng/ml, n5 50), with (n5 131) or
without (n5 151) MTX. Sixty-nine patients also received anti-hu-
man T- lymphocyte immunoglobulin (ATG, 5-10 mg/kg). Except
for the stem cell sources, there were no significant differences be-
tween the C- and F-groups. Acute renal failure (ARF) within 100
days was defined as there was a greater than two-fold rise in the se-
rum creatinine concentration compared to the baseline. The me-
dian follow-up in surviving patients was 1589 days (50-3291).
The 275 patients who survived more than 30 days (except for
one patient who died of relapse) all achieved neutrophil engraft-
ment in a median 13 days (range, 5-42 days). No significant differ-
ence was observed between C- and F-group with regard to OS
(59% vs 48% at 3 y, p5 0.20), relapse rate (42% vs 35% at 3 y,
p5 0.42), NRM (7% vs 6% on d100, 22% vs 32% at 3 y,
p5 0.15), or the cumulative incidences of ARF (34% vs 27% on
d 100, p5 0.26), grade II-IV acute GVHD (46% vs 47%,
p5 0.40), and extensive chronic GVHD (62% vs 54% at 3 y,
p5 0.21). Multivariate analyses showed that TBI [HR 2.96 (1.86-
4.72), p\0.001] for NRM, TBI [HR 1.75 (1.23-2.49), p5 0.002]and high-risk disease [HR 2.39 (1.62-3.55), p\0.001] for OS,
and TBI [HR 1.98 (1.25-3.14), p5 0.004] and CSP [HR 2.10
(1.06-4.17), p5 0.03] for ARF were significant factors for poor
outcomes. However, 2CdA was not significantly associated with
NRM, OS or ARF. Our study suggested that a relatively low
dose of 2CdA was tolerable and feasible as part of a reduced-
intensity regimen, and was not associated with any significant
nephrotoxicities.316
TANDEM AUTO-ALLO IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN
FIRST COMPLETE REMISSION (CR)
Castagna, L.1, Prebet, T.1, Fu¨rst, S.1, El-Cheikh, J.1, Charbonnier, A.1,
Faucher, C.1,Mohty,M.2, Chabannon, C.3, Vey, N.1, Blaise, D.1 1 Institut
Paoli Calmettes,Marseille, France; 2Hotel Dieu, Nantes, France; 3 Institut
Paoli Calmettes, Marseille, France
Background: High and intermediate risk AML can benefit from
allo-SCT in first CR. Reduced intensity conditionings (ALLO-
RIC) decreases toxicity. However there are now data in favour of
lower disease control as compared with standard CDT.We hypoth-
esized that if a better quality of remission could be achieved, the re-
lapse incidence could be lowered.
Patients and methods: From 2001 to 2008, 31 AML patients in
first CR received a tandem auto-allo program. At diagnosis, me-
dian number of WBC was 3  10e9/l (0.9-235), 13% of patients
have extramedullary localisations. 64% of patients were considered
at high-risk (cytogenetic, secondary disease or double inductions)
and 36% at intermediate risk. After reaching CR1, all but two pa-
tients received a consolidation course with high-dose cytarabine
(HD-ARAC, 24 g/m2 in 93%) CT, followed by autologous stem
cell harvest. HD melphalan (HD-PAM 140 mg/m2) was followed
by autologous stem cells reinfusion. Then, ALLO-RIC consisted
of fludarabine (90 mg/m2) plus (2 Gy) TBI (3 pts) or fludarabine
(150 mg/m2), busulfan over 2 days, and thymoglobuline (2.5 or
5 mg/kg). GVHD prophylaxis was CyA. 3 patients received also
mycofenolate mofetil. All donors, but one, were HLA identical
sibling. The median number of allo CD34+ cells was 6.1 
10e6/Kg. Prognostic scores (HCT-CI, PAM, EBMT) were retro-
spectively calculated for each patient. All pts have a performance
status$ 90%.
Results:Median fup from diagnosis and ALLO-RICwere 40 and 34
months, respectively. Median days between last CT and HD-PAM
was 51 (30-77) and between HD-PAM and ALLO-RIC was 69
(55-176). 5 pts relapsed for a 4 year CI of 15% (3-29). At last fup,
13 have died (relapse: 5; toxicity: 8). Grade II-IV aGVHD and
cGVHD CI were respectively 26% and 65% (extensive 84%).
GVHD was the cause of death in seven pts. Six pts (19%) reactived
CMV, and 1 pt did not survive to an interstitial pneumonitis. The
4-year overall survival (OS), relapse free survival (RFS), and 1-year
TRMwere 61% (43-76), 59% (41-75), and 16% (3-29), respectively.
In multivariate analysis, prognostic scores did not influence TRM
and OS.
Conclusions:This report showed that i) tandem auto-allo is feasible
in AML pts; ii) acute GVHD incidence is not increased; iii) prognos-
tic scores did not impact on TRM and survival; iv) TRM is low with
GVHDasmain cause of death; v) low relapse rate is documented and
invites further development.317
LONG TERM OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
El-Emary, M.1, Al Khabori, M.1, Buitron, N.1, Messner, H.1, Lipton, J.1,
Gupta, V.1, Kuruvilla, J.1, Xu, W.2, Galal, A.1 1Princess Margaret Hos-
pital, University of Toronto, Toronto, ON, Canada; 2Princess Margaret
Hospital, University of Toronto, Toronto, ON, Canada
Introduction: Allogeneic Stem Cell Transplantation (Al-SCT) re-
mains an option for patients with advanced Chronic Lymphocytic
Leukemia (CLL) with high risk features.
